Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · IEX Real-Time Price · USD
135.99
-1.77 (-1.28%)
At close: Apr 26, 2024, 4:00 PM
135.15
-0.84 (-0.62%)
After-hours: Apr 26, 2024, 5:10 PM EDT
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,400 employees on December 31, 2023. The number of employees increased by 200 or 16.67% compared to the previous year.
Employees
1,400
Change (1Y)
200
Growth (1Y)
16.67%
Revenue / Employee
$1,347,929
Profits / Employee
$178,357
Market Cap
13.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Quest Diagnostics | 48,000 |
Viatris | 38,000 |
Teva Pharmaceutical | 37,851 |
Dr. Reddy's Laboratories | 25,863 |
Revvity | 11,500 |
BioMarin Pharmaceutical | 3,401 |
ShockWave Medical | 1,468 |
NBIX News
- 3 days ago - Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community - PRNewsWire
- 5 days ago - Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder - PRNewsWire
- 12 days ago - Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 - GlobeNewsWire
- 17 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results - PRNewsWire
- 24 days ago - Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder - PRNewsWire
- 4 weeks ago - Three top U.S. biotech stocks to buy in April - Invezz
- 4 weeks ago - Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences to Participate at Virtual Investor Conferences in March - PRNewsWire